India, July 14 -- Shares of Dare Bioscience, Inc. (DARE) surged over 135% on Monday morning after the company announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating the contraceptive effectiveness, safety and acceptability of Ovaprene, the company's investigational monthly, hormone-free intravaginal contraceptive.
DARE is currently trading at $5.95, up $3.44 or 136.51%, on a huge volume of 45.3 million shares, above average volume of 163 thousand, on the Nasdaq. The stock opened its trading at $7.93 after closing Friday at $2.52. The stock has traded between $2.11 and $9.19 in the past 52-week period.
There currently are no FDA-approved, hormone-free, monthly intravaginal contraceptives....